BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Interest Income

Income earned on cash, deposits, and investments held by the company.

BioAge Labs, Inc.NASDAQ: BIOA

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income dips below year-ago levels

Q1 FY2026 interest income of $3.27M fell 12.0% year over year, behind the +4.9% change in trailing-twelve-month interest income. Sequentially, it rose 17.0% from the prior quarter. Over 3 fiscal years it compounded at +204.2% a year.

Context

  • Interest income amounted to 145.5% of revenue in FY2025.
  • Interest income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.0% toward the trailing-twelve-month pace of +4.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.27M+17.0% QoQ
Last fiscal yearDec 2025
$13.09M+35.9% YoY
LTMMar 2026
$12.64M+4.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.0%——
1 year+35.9%——
3-year CAGR+204.2%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
13.09M USD
Year-over-year change
+35.9%
3-year CAGR
+204.2%

Interest Income vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.9% is the 2nd highest of 8, against a peer median of -39.6%.
  • Interest income amounts to 122.5% of revenue for BIOA, versus a peer median of 2.8%.
BIOA Competitors
Interest Income for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$17.35M USD-14.3%+61.7%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$14.02M USD-40.6%+13.7%—
BIOABioAge Labs, Inc.LTM Mar 2026$12.64M USD+4.9%+204.2%122.5%
CGCCanopy Growth CorporationLTM Mar 2026CA$11.15M CAD+26.5%-25.6%3.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$6.6M CAD-42.6%-32.4%2.1%
CABACabaletta Bio, Inc.LTM Mar 2026$5.62M USD-34.1%+73.0%—
HUMAHumacyte, Inc.LTM Mar 2026$2.26M USD-39.6%-0.5%111.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$401K USD——0.3%
TKNOAlpha Teknova, Inc.LTM Mar 2026$0 USD——0.0%
EDITEditas Medicine, Inc.LTM Mar 2026-$1.51M USD-112.9%+14.6%3.9%
Peer median (excluding BIOA) —-39.6%+13.7%2.8%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.